# SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

> **NCT07549399** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 204 (estimated)

## Conditions studied

- Rectal Adenocarcinoma
- High-Risk Cancer
- MSS

## Interventions

- **RADIATION:** Short-Course Radiotherapy
- **DRUG:** PD-1 monoclonal antibody
- **DRUG:** mFOLFOX6 regimen
- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT07549399
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549399, "SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07549399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*